Technical Analysis for TRIL - Trillium Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 7.26 0.41% 0.03
TRIL closed up 0.41 percent on Friday, July 10, 2020, on 47 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical TRIL trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish 0.41%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.41%
Bollinger Band Squeeze Range Contraction 0.41%
Oversold Stochastic Weakness 0.41%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. For more information visit: www.trilliumtherapeutics.com
Medicine Cancer Medical Specialties Immunology Treatment Of Cancer Immune System Tumor Acute Myeloid Leukemia Cancer Immunotherapy Monoclonal Antibody Antibody Drug Conjugates Cancer Research CD47

Is TRIL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.66
52 Week Low 0.24
Average Volume 2,062,623
200-Day Moving Average 3.51
50-Day Moving Average 7.11
20-Day Moving Average 8.00
10-Day Moving Average 7.61
Average True Range 0.67
ADX 19.97
+DI 19.37
-DI 19.11
Chandelier Exit (Long, 3 ATRs ) 7.66
Chandelier Exit (Short, 3 ATRs ) 9.05
Upper Bollinger Band 9.14
Lower Bollinger Band 6.86
Percent B (%b) 0.17
BandWidth 28.49
MACD Line 0.04
MACD Signal Line 0.23
MACD Histogram -0.1914
Fundamentals Value
Market Cap 78.37 Million
Num Shares 10.8 Million
EPS -4.08
Price-to-Earnings (P/E) Ratio -1.78
Price-to-Sales 0.00
Price-to-Book 4.22
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.80
Resistance 3 (R3) 7.80 7.62 7.71
Resistance 2 (R2) 7.62 7.48 7.62 7.68
Resistance 1 (R1) 7.44 7.40 7.53 7.44 7.65
Pivot Point 7.26 7.26 7.31 7.26 7.26
Support 1 (S1) 7.08 7.12 7.17 7.08 6.87
Support 2 (S2) 6.90 7.04 6.90 6.84
Support 3 (S3) 6.72 6.90 6.81
Support 4 (S4) 6.72